Mark Purcell
Stock Analyst at Morgan Stanley
(1.04)
# 3,704
Out of 4,896 analysts
5
Total ratings
50%
Success rate
-9.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $121.02 | -5.80% | 1 | Jan 23, 2024 | |
| SNY Sanofi | Initiates: Equal-Weight | $55 | $48.61 | +13.15% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $38.28 | +14.94% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $71.13 | +19.50% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $68.93 | +74.09% | 1 | Jan 23, 2024 |
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $121.02
Upside: -5.80%
Sanofi
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $48.61
Upside: +13.15%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $38.28
Upside: +14.94%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $71.13
Upside: +19.50%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $68.93
Upside: +74.09%